Alicia Ault

The annual NSDUH also tracked fentanyl for the first time, reporting that 0.4% of Americans misused either a prescription or illegally manufactured form of the drug.

A study found that transgender individuals older than 50 years experiencing severe psychological distress and discrimination, harassment, and violence in multiple aspects of their lives had the highest risk.

Clinicians question the group’s methodology, but the Lown Institute, that produced the report, stands by its methods and conclusions.

Purveyors on coupon sites like Groupon are marketing weight loss programs that include compounded semaglutide and tirzepatide.

The medications can reduce or eliminate weight-related complications in children but are in short supply, and insurers are denying coverage, said pediatricians.

The street drug bromazolam, an illicit benzodiazepine, is tied to seizures and coma and is showing up with increasing frequency in the US illicit drug supply.

Newly released documents show that the FDA has determined that cannabis has legitimate medical use and that it should be moved from Schedule I to Schedule III on the controlled substances list.

The most expensive gene therapy on the US market may give payers pause, said study authors.

A dramatic increase in law enforcement seizures of psilocybin-containing “magic mushrooms” likely indicates growing use and public acceptance of the psychedelic.

A final federal rule that allows telehealth initiation of treatment and take-home doses of methadone increases access and removes stigma, say clinicians.

A court victory on rescheduling psilocybin leads the plaintiffs to believe that a separate pending case could allow the drug’s use under right-to-try laws.

Use of methamphetamine and cocaine among those also using fentanyl reached a record high in 2023, a new report showed, more evidence of a “fourth wave” in the opioid epidemic.

Nearly 18 months after the FDA first acknowledged a national shortage of Adderall, there is now a widespread scarcity of multiple ADHD medications — with no end in sight.

Investigative sleuths say the rewards are high while consequences are almost nonexistent, all while investigations take years to complete.

The watchdog group Public Citizen is calling for the prompt removal of the ALS drug Relyvrio after it failed to meet primary and secondary endpoints in top-line results from a phase 3 trial.

Some 321,000 state employees would be eligible, at a cost of about $357,000 per year, according to one analysis.

The Special Diabetes Program supports type 1 research and efforts to less the burden of type 2 diabetes on American Indians and Alaska Natives.

The FDA embraces the use of biomarkers and surrogate endpoints in its most recent guidance on developing therapeutics for early Alzheimer’s disease.

The US Food and Drug Administration has approved the first-ever prescription app for major depressive disorder.

The first US clinical guidelines for adult ADHD are expected to be released this fall, providing a long-overdue, much-needed, standardized framework.